Covid 19 coronavirus: With all eyes on Covid-19, drug-resistant infections crept in
28 Jan, 2021 05:00 AM
6 minutes to read
A medical worker disinfects the ICU ward once designated for Covid-19 patients in Wuhan, China. Photo / Getty Images
A medical worker disinfects the ICU ward once designated for Covid-19 patients in Wuhan, China. Photo / Getty Images
New York Times
By: Matt Richtel
The spread of other dangerous germs is surging a result, in part, of the chaotic response to the pandemic. As Covid-19 took hold over the past year, hospitals and nursing homes used and reused scarce protective equipment masks, gloves, gowns. This desperate frugality helped prevent the airborne transfer of the virus.
Paul S. Schulz, M.D.
Dr. Schulz received his Bachelor of Science in chemical engineering at University of Cincinnati, Ohio, in 1992 and his medical degree from the University of Louisville in 1999. He continued on with the University of Louisville School of Medicine to complete an internal medicine residency and infectious diseases fellowship in 2005. He remained on faculty until 2007 when he joined a private practice group. In 2010, Dr. Schulz joined Norton Healthcare and currently serves as the system epidemiologist participating in antimicrobial stewardship, infection prevention, and employee health. As part of the infectious diseases PGY2 program, he precepts the longitudinal ambulatory infectious diseases rotation and adult infectious diseases consult service. His current area of interest is HIV/hepatitis C co-infection.
Managing Editor
The first vaccine to prevent COVID-19 has been cleared for use in the United States. The Food and Drug Administration on Saturday granted emergency use authorization to Pfizer and BioNTech’s COVID-19 vaccine for use in individuals 16 years old and older. The first shipments began leaving facilities on Sunday.
The FDA’s decision was based on data from its Phase 3 clinical study, whose results were published last week in the New England Journal of Medicine and which saw a 95% vaccine efficacy rate. The two companies continue to gather additional data and prepare a biologics license application for full approval from the FDA in 2021.